GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » E10

Revance Therapeutics (Revance Therapeutics) E10 : $-4.52 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Revance Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.580. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.52 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-21), Revance Therapeutics's current stock price is $3.01. Revance Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-4.52. Revance Therapeutics's Shiller PE Ratio of today is .


Revance Therapeutics E10 Historical Data

The historical data trend for Revance Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics E10 Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -4.54 -4.63

Revance Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.78 -4.63 -4.60 -4.63 -4.52

Competitive Comparison of Revance Therapeutics's E10

For the Biotechnology subindustry, Revance Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Shiller PE Ratio falls into.



Revance Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Revance Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.58/131.7762*131.7762
=-0.580

Current CPI (Mar. 2024) = 131.7762.

Revance Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.690 100.560 -0.904
201409 -0.600 100.428 -0.787
201412 -0.600 99.070 -0.798
201503 -0.650 99.621 -0.860
201506 -0.710 100.684 -0.929
201509 -0.810 100.392 -1.063
201512 -0.830 99.792 -1.096
201603 -0.710 100.470 -0.931
201606 -0.880 101.688 -1.140
201609 -0.640 101.861 -0.828
201612 -0.950 101.863 -1.229
201703 -0.940 102.862 -1.204
201706 -0.900 103.349 -1.148
201709 -1.010 104.136 -1.278
201712 -1.140 104.011 -1.444
201803 -0.970 105.290 -1.214
201806 -0.940 106.317 -1.165
201809 -0.910 106.507 -1.126
201812 -1.120 105.998 -1.392
201903 -0.850 107.251 -1.044
201906 -0.860 108.070 -1.049
201909 -0.960 108.329 -1.168
201912 -0.990 108.420 -1.203
202003 -1.150 108.902 -1.392
202006 -1.120 108.767 -1.357
202009 -1.340 109.815 -1.608
202012 -1.240 109.897 -1.487
202103 -1.080 111.754 -1.273
202106 -1.070 114.631 -1.230
202109 -1.100 115.734 -1.252
202112 -0.930 117.630 -1.042
202203 -0.940 121.301 -1.021
202206 -0.880 125.017 -0.928
202209 -1.170 125.227 -1.231
202212 -1.820 125.222 -1.915
202303 -0.740 127.348 -0.766
202306 -0.800 128.729 -0.819
202309 -1.630 129.860 -1.654
202312 -0.630 129.419 -0.641
202403 -0.580 131.776 -0.580

Add all the adjusted EPS together and divide 10 will get our e10.


Revance Therapeutics  (NAS:RVNC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Revance Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080